Symbol | Exchange | Currency |
|---|
Jounce Therapeutics (JNCE): Q1 GAAP EPS of -$0.58 beats by $0.01.Revenue of $1.54M misses by $10.27M.Cash, cash equivalents and investments increased to $271.3M.Press Release
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature--...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | Sell |
| Summary | Buy | Buy | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,430.20 | 2,441.72 | 2,418.96 | -4.93 | -0.20% | 1.10M | NASDAQ | |||
| 331.26 | 332.83 | 328.93 | -1.20 | -0.36% | 13.59M | NASDAQ | |||
| 33.10 | 33.41 | 32.80 | +0.23 | +0.70% | 788.24K | NYSE | |||
| 193.02 | 200.05 | 192.88 | -23.75 | -10.96% | 13.73M | NASDAQ | |||
| 67.34 | 67.94 | 66.78 | -0.05 | -0.07% | 9.54M | NYSE | |||
| 29.32 | 29.35 | 29.13 | +0.14 | +0.48% | 31.09M | NYSE | |||
| 71.44 | 71.49 | 70.33 | +0.97 | +1.38% | 2.89M | NYSE | |||
| 211.64 | 213.46 | 211.00 | -1.43 | -0.67% | 12.28M | NYSE | |||
| 0.931 | 1.01 | 0.00 | -0.079 | -7.78% | 3.56M | NASDAQ | |||
| 220.70 | 227.92 | 220.03 | -5.03 | -2.23% | 8.73M | NYSE | |||
| 1.14 | 1.15 | 1.12 | -0.010 | -0.87% | 145.17K | NASDAQ | |||
| 49.40 | 49.60 | 42.01 | +6.59 | +15.39% | 218.01M | NYSE | |||
| 271.45 | 271.90 | 268.40 | +1.98 | +0.73% | 4.49M | NASDAQ | |||
| 15.85 | 16.19 | 15.68 | +0.220 | +1.41% | 2.00M | NASDAQ | |||
| 45.68 | 46.26 | 42.76 | +2.92 | +6.83% | 85.73M | NYSE |
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.
